Evidence-Based Complementary and Alternative Medicine
Volume 2016 (2016), Article ID 7173896, 1 page
http://dx.doi.org/10.1155/2016/7173896

Corrigendum

Corrigendum to “IQP-VV-102, a Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety”

Barbara Grube,¹ Udo Bongartz,² and Felix Alt³

¹Practice for General Medicine, Kurfürstendamm 157/158, 10709 Berlin, Germany
²Analyze & Realize GmbH, Weißenseer Weg 111, 10369 Berlin, Germany
³Analyze & Realize GmbH, Waldseeweg 6, 13467 Berlin, Germany

Received 18 October 2016; Accepted 16 November 2016

Copyright © 2016 Barbara Grube et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “IQP-VV-102, a Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety” [1], there was an error under Section : Hip Circumference, which should be corrected as follows.

3.1.3. Hip Circumference. The mean hip circumference in the IQP-VV-102 group at baseline (V2) was 108.1 cm (SD 6.7) while the placebo group was 106.5 cm (SD 6.5) ().

In addition, the declaration statement in the Conflict of Interests section “The authors declare that there is no conflict of interests regarding the publication of this paper” should be replaced with the following declaration “InQpharm Europe Ltd. is the manufacturer of the investigational product and oversaw the trial and manuscript preparation as the sponsor.”

References

B. Grube, U. Bongartz, and F. Alt, “IQP-VV-102, a novel proprietary composition for weight reduction: a double-blind randomized clinical trial for evaluation of efficacy and safety,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 413075, 7 pages, 2015.